Baillie Gifford & CO Enanta Pharmaceuticals Inc Transaction History
Baillie Gifford & CO
- $127 Billion
- Q4 2024
Shares
2 transactions
Others Institutions Holding ENTA
# of Institutions
108Shares Held
19.7MCall Options Held
9.7KPut Options Held
12.4K-
Krensavage Asset Management, LLC New York, NY2.12MShares$13.4 Million7.2% of portfolio
-
Farallon Capital Management LLC San Francisco, CA2.11MShares$13.3 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.98MShares$12.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.85MShares$11.7 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.22MShares$7.71 Million0.0% of portfolio
About ENANTA PHARMACEUTICALS INC
- Ticker ENTA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,724,900
- Market Cap $131M
- Description
- Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...